Serum undercarboxylated osteocalcin level increases with 48 weeks of teriparatide treatment in pre-treated elderly rheumatoid arthritis patients who use anti-resorptive drugs.
J Endocrinol Invest
; 35(9): 796-9, 2012 Oct.
Article
en En
| MEDLINE
| ID: mdl-23135318
ABSTRACT
AIM:
The serum undercarboxylated osteocalcin (ucOC) level, a biochemical bone marker of vitamin K insufficiency, is often affected by anti-osteoporosis drugs. There have been no reports regarding the relationship between ucOC and teriparatide. SUBJECTS ANDMETHODS:
We conducted a prospective observational study of 26 female rheumatoid arthritis (RA) patients. The patients were divided into 3 groups those who underwent a direct switch from anti-resorptive drugs to teriparatide (12 cases), those who started teriparatide without pre-treatment (5 cases), and the control patients (9 cases). The median age (interquartile range) of the patients in each group was 75 (67-77), 82 (78-84), and 69 (62-80) yr, respectively. All patients, except controls, received 48-week treatments of teriparatide. We analyzed the median 48-week changes from baseline of the serum ucOC levels with the Steel-Dwass method.RESULTS:
The median change from baseline in the direct switch group was higher than that in other groups (p<0.05).CONCLUSIONS:
The serum ucOC levels increased with treatment of teriparatide in elderly RA patients, especially when the patients received pre-treatment.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Artritis Reumatoide
/
Ácidos Carboxílicos
/
Biomarcadores
/
Densidad Ósea
/
Osteocalcina
/
Teriparatido
/
Conservadores de la Densidad Ósea
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Endocrinol Invest
Año:
2012
Tipo del documento:
Article
País de afiliación:
Japón